GlassScriptPhysician profile
Esfandiar Mafi
NPI 1780656447
$2,771.46
in general payments reported to CMS, 2019-2025
38 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.82 · 2021: $120 · 2022: $398 · 2023: $384 · 2024: $988 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $313.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $251.96 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $225.83 | 2024-2025 | Entyvio |
| Pfizer INC. | $185.18 | 2021-2025 | |
| Abbvie INC. | $183.33 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $166.60 | 2024-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $112.77 | 2021-2022 | |
| Novo Nordisk INC | $104.69 | 2023-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $103.85 | 2022-2024 | Verquvo, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $102.53 | 2021-2023 | Eliquis |
| Daiichi Sankyo INC. | $97.28 | 2022-2024 | Injectafer |
| Amgen INC. | $76.45 | 2020-2022 | |
| Lilly USA, LLC | $76.14 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $68.99 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $66.42 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esfandiar Mafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.